Gen Ilac ve Saglik Urunleri A.S. (GENIL)
XIST XIST Primary Summary
Gen Ilac ve Saglik Urunleri A.S. (GENIL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Gen Ilac ve Saglik Urunleri A.S. ever had a stock split?
Gen Ilac ve Saglik Urunleri A.S. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Abidin Gulmus CEO | XIST Exchange | TREGENL00024 ISIN |
| TR Country | 682 Employees | 12 Nov 2025 Last Dividend | 10 Feb 2026 Last Split | - IPO Date |
Overview
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi is a distinguished pharmaceutical company dedicated to the manufacturing and supply of specialized products targeting rare diseases and disorders on a global scale. Incorporated in 1997 and based in Çankaya, Turkey, the company stands out for its comprehensive approach to addressing the needs of patients across various medical disciplines. In its pursuit of innovation and excellence, Gen Ilac has entered into a notable collaboration and licensing agreement with Sulfateq BV, aiming to pioneer the development and commercialization of SUL-238. This original molecule has the potential to offer a unique treatment solution for Alzheimer's disease and other neurodegenerative diseases, marking a significant milestone in the company's commitment to advancing medical science and patient care.
Products and Services
- Neurology - Focused on addressing disorders of the nervous system, the neurology range includes treatments that are part of the innovative collaboration for Alzheimer's disease and other neurodegenerative conditions.
- Endocrinology - This area targets hormonal disorders, providing therapies that manage and treat conditions affecting the endocrine glands, offering hope and improved quality of life to patients suffering from these diseases.
- Nephrology - Specializing in the care of kidney-related disorders, the nephrology portfolio offers advanced treatments for chronic kidney diseases and conditions affecting renal function, aiming to enhance patient well-being.
- Oncology - The oncology segment provides innovative cancer therapies. These treatments are designed to fight various types of cancer, supporting patients throughout their treatment journey with cutting-edge medicine.
- Hematology - This field focuses on diseases related to the blood, offering therapies for conditions such as hematologic malignancies. The hematology range underscores the company's commitment to combating blood disorders with effective solutions.
- Pediatric - Dedicated to the youngest patients, the pediatric range encompasses treatments specifically formulated for children, addressing a wide spectrum of diseases and disorders with pediatric needs in mind.
